The likelihood of antitumor immune response to anti-PD-1 antibody therapy is closely linked to expression of PD-L1 on the tumor cell surface (Brahmer et al., 2010; Pardoll, 2012; Taube et al., 2014). This evidence concerns the gene CD274 and neoplasm.